Published in Int J Radiat Oncol Biol Phys on November 01, 2009
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol (2013) 1.01
Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol (2012) 0.97
Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Front Oncol (2014) 0.94
Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. Radiat Oncol (2014) 0.81
Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim (2013) 0.80
Dosimetric impact of number of treatment fields in uniform scanning proton therapy planning of lung cancer. J Med Phys (2014) 0.77
Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancer. J Radiat Res (2014) 0.77
Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. Cancers (Basel) (2015) 0.76
Feasibility of proton transmission-beam stereotactic ablative radiotherapy versus photon stereotactic ablative radiotherapy for lung tumors: a dosimetric and feasibility study. PLoS One (2014) 0.75
Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol (2017) 0.75
Giving oligometastases the best shot using stereotactic body radiosurgery with image guidance. How far is the cat out of the bag? J Gastrointest Oncol (2010) 0.75
Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy. Radiat Oncol (2017) 0.75
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2009) 6.11
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol (2012) 4.27
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2011) 4.12
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res (2006) 3.15
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol (2006) 2.83
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Radiosurgery to the postoperative surgical cavity: who needs evidence? Int J Radiat Oncol Biol Phys (2011) 2.21
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.83
Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage (2007) 1.83
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol (2003) 1.76
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.74
Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol (2012) 1.74
Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.69
Benzoic acid glucosinolate esters and other glucosinolates from Arabidopsis thaliana. Phytochemistry (2002) 1.69
Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.65
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.62
Central nervous system tumors. Mayo Clin Proc (2007) 1.61
Silver nanoparticles and polymeric medical devices: a new approach to prevention of infection? J Antimicrob Chemother (2004) 1.58
Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys (2007) 1.54
Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg (2009) 1.51
Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg (2010) 1.49
Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys (2005) 1.46
Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. Am J Clin Oncol (2011) 1.45
Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery (2006) 1.42
Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery (2008) 1.42
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg (2008) 1.37
Reversible, strokelike migraine attacks in patients with previous radiation therapy. Neuro Oncol (2003) 1.36
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys (2009) 1.34
Radiosurgery for arteriovenous malformations of the basal ganglia, thalamus, and brainstem. J Neurosurg (2004) 1.31
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys (2006) 1.28
Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer (2003) 1.28
Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol (2002) 1.26
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol (2014) 1.24
Motivational readiness for physical activity and quality of life in long-term lung cancer survivors. Lung Cancer (2008) 1.23
Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci (2008) 1.23
Cognitive sequelae of brain radiation in adults. Semin Oncol (2004) 1.22
Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys (2006) 1.22
Stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg (2002) 1.22
Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol (2008) 1.20
A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys (2005) 1.20
Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology (2007) 1.18
Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys (2008) 1.17
Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study. Radiother Oncol (2006) 1.17
Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol (2011) 1.17
Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys (2006) 1.16
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol (2009) 1.16
Randomized controlled trial of maintaining quality of life during radiotherapy for advanced cancer. Cancer (2012) 1.15
A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2003) 1.13
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol (2009) 1.12
Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery (2002) 1.12
Resectable pancreatic small cell carcinoma. Rare Tumors (2011) 1.11
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol (2011) 1.10
Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys (2003) 1.10
Re: Proton vs intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2013) 1.10
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res (2010) 1.08
Stereotactic radiosurgery for brainstem metastases: Survival, tumor control, and patient outcomes. Int J Radiat Oncol Biol Phys (2006) 1.08
Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer (2012) 1.08
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys (2011) 1.07
Role of camalexin, indole glucosinolates, and side chain modification of glucosinolate-derived isothiocyanates in defense of Arabidopsis against Sclerotinia sclerotiorum. Plant J (2011) 1.07
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 1.06
Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys (2007) 1.04
Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys (2007) 1.04
Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol (2011) 1.04
Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study. J Support Oncol (2009) 1.04
Prognosis and treatment of spinal cord astrocytoma. Int J Radiat Oncol Biol Phys (2008) 1.04
Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol (2008) 1.04
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol (2013) 1.03
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol (2013) 1.03
Measuring spiritual quality of life in patients with cancer. J Support Oncol (2007) 1.03
Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol (2007) 1.02
Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys (2010) 1.02
Antimicrobial resistance of Escherichia coli isolates from broiler chickens and humans. BMC Vet Res (2006) 1.02
Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys (2012) 1.02
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys (2013) 1.02
A methodology to determine margins by EPID measurements of patient setup variation and motion as applied to immobilization devices. Med Phys (2004) 1.01